Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Is the era of sorafenib over? A review of the literature
Guanghan Fan, Xuyong Wei, Xiao Xu
Therapeutic Advances in Medical Oncology (2020) Vol. 12
Open Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

The functional roles of the circRNA/Wnt axis in cancer
Chen Xue, Ganglei Li, Qiuxian Zheng, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 96
Biomedical Applications of Plant Extract-Synthesized Silver Nanoparticles
Sohail Simon, Nicole Remaliah Samantha Sibuyi, Adewale Oluwaseun Fadaka, et al.
Biomedicines (2022) Vol. 10, Iss. 11, pp. 2792-2792
Open Access | Times Cited: 77
The mechanism of ferroptosis and its related diseases
Shijian Feng, Dan Tang, Yichang Wang, et al.
Molecular Biomedicine (2023) Vol. 4, Iss. 1
Open Access | Times Cited: 69
SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase
Feng-li Xu, Xiaohong Wu, Chang Chen, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 47
Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents
Ali Doostmohammadi, Hossein Jooya, Kimia Ghorbanian, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 40
Heterogeneity of hepatocellular carcinoma: from mechanisms to clinical implications
Fatema Safri, Romario Nguyen, Shadi Zerehpooshnesfchi, et al.
Cancer Gene Therapy (2024) Vol. 31, Iss. 8, pp. 1105-1112
Open Access | Times Cited: 31
Advances in Drug Targeting, Drug Delivery, and Nanotechnology Applications: Therapeutic Significance in Cancer Treatment
Fatih Çiftçi, Ali Can Özarslan, İmran Cagri Kantarci, et al.
Pharmaceutics (2025) Vol. 17, Iss. 1, pp. 121-121
Open Access | Times Cited: 3
SCARA5 deficiency inhibits ferroptosis via regulating iron homeostasis and results in sorafenib resistance in hepatocellular carcinoma
Cong Chen, Lan Wang, Xiaofang Cui, et al.
Cellular Signalling (2025), pp. 111656-111656
Closed Access | Times Cited: 2
Crosstalk between Macrophages, T Cells, and Iron Metabolism in Tumor Microenvironment
Lesang Shen, Yunxiang Zhou, Haifei He, et al.
Oxidative Medicine and Cellular Longevity (2021) Vol. 2021, Iss. 1
Open Access | Times Cited: 65
Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-κB pathways and LncRNA-AF085935/GPC3 axis
Tohada M. AL‐Noshokaty, Noha M. Mesbah, Dina M. Abo‐Elmatty, et al.
Life Sciences (2022) Vol. 303, pp. 120675-120675
Closed Access | Times Cited: 54
The cubosome-based nanoplatforms in cancer therapy: Seeking new paradigms for cancer theranostics
B.H. Jaswanth Gowda, Mohammed Gulzar Ahmed, Saad Ali Alshehri, et al.
Environmental Research (2023) Vol. 237, pp. 116894-116894
Closed Access | Times Cited: 28
Current therapeutic modalities and chemopreventive role of natural products in liver cancer: Progress and promise
Amit Kumar Singh, Shiv Vardan Singh, Ramesh Kumar, et al.
World Journal of Hepatology (2023) Vol. 15, Iss. 1, pp. 1-18
Open Access | Times Cited: 27
Pathogenesis of Hepatocellular Carcinoma: The Interplay of Apoptosis and Autophagy
Elias Kouroumalis, Ioannis Tsomidis, Argyro Voumvouraki
Biomedicines (2023) Vol. 11, Iss. 4, pp. 1166-1166
Open Access | Times Cited: 23
Gastrointestinal side effects in hepatocellular carcinoma patients receiving transarterial chemoembolization: a meta-analysis of 81 studies and 9495 patients
Nathalie Arendt, Maria Kopsida, Jaafar Khaled, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access | Times Cited: 1
Self‐Activated Cascade‐Responsive Sorafenib and USP22 shRNA Co‐Delivery System for Synergetic Hepatocellular Carcinoma Therapy
Shengjun Xu, Sunbin Ling, Qiaonan Shan, et al.
Advanced Science (2021) Vol. 8, Iss. 5
Open Access | Times Cited: 50
ATF4 protects against sorafenib-induced cardiotoxicity by suppressing ferroptosis
Hui Jiang, Cong Wang, An Zhang, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 153, pp. 113280-113280
Open Access | Times Cited: 36
Integrated analysis of histone lysine lactylation (Kla)-specific genes suggests that NR6A1, OSBP2 and UNC119B are novel therapeutic targets for hepatocellular carcinoma
Qinjuan Wu, Xin Li, Menghong Long, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 19
Targeting Akt in Hepatocellular Carcinoma and Its Tumor Microenvironment
Mariam Mroweh, Gaël S. Roth, Thomas Decaens, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 4, pp. 1794-1794
Open Access | Times Cited: 36
Autophagy‐Dependent Ferroptosis as a Therapeutic Target in Cancer
Li Liu, Liqi Li, Menghuan Li, et al.
ChemMedChem (2021) Vol. 16, Iss. 19, pp. 2942-2950
Closed Access | Times Cited: 32
Peroxisome proliferator-activated receptor gamma as a therapeutic target for hepatocellular carcinoma: Experimental and clinical scenarios
Swati Katoch, Vinesh Sharma, Vikram Patial
World Journal of Gastroenterology (2022) Vol. 28, Iss. 28, pp. 3535-3554
Open Access | Times Cited: 22
Deciphering the role of transforming growth factor-beta 1 as a diagnostic-prognostic-therapeutic candidate against hepatocellular carcinoma
Aswathy R. Devan, K Pavithran, Bhagyalakshmi Nair, et al.
World Journal of Gastroenterology (2022) Vol. 28, Iss. 36, pp. 5250-5264
Open Access | Times Cited: 20
Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis
Jia Deng, Ziyue Liao, Jian Gao
Current Oncology (2023) Vol. 30, Iss. 1, pp. 1243-1254
Open Access | Times Cited: 13
The role of tumor‐associated macrophages in hepatocellular carcinoma progression: A narrative review
Xinyi Zhang, Chao Yu, Siqi Zhao, et al.
Cancer Medicine (2023) Vol. 12, Iss. 24, pp. 22109-22129
Open Access | Times Cited: 12
Phenotypic Screening of Prospective Analgesics Among FDA‐Approved Compounds using an iPSC‐Based Model of Acute and Chronic Inflammatory Nociception
Bryan J. Black, Rasha El Ghazal, Neal M. Lojek, et al.
Advanced Science (2024) Vol. 11, Iss. 11
Open Access | Times Cited: 4
Salvage locoregional therapies for recurrent hepatocellular carcinoma
Cody R. Criss, Mina S. Makary
World Journal of Gastroenterology (2023) Vol. 29, Iss. 3, pp. 413-424
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top